Exploring the Formation Kinetics of Octacalcium Phosphate from Alpha-Tricalcium Phosphate: Synthesis Scale-Up, Determination of Transient Phases, Their Morphology and Biocompatibility.


Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
02 03 2023
Historique:
received: 09 01 2023
revised: 17 02 2023
accepted: 28 02 2023
medline: 30 3 2023
entrez: 29 3 2023
pubmed: 30 3 2023
Statut: epublish

Résumé

Even with decades of research studies behind octacalcium phosphate (OCP), determination of OCP phase formation has proved to be a cumbersome challenge. Even though obtaining a large quantity of OCP is important for potential clinical uses, it still remains a hindrance to obtain high yields of pure OCP. Taking that into consideration, the purpose of this study was to scale-up OCP synthesis for the first time and to use a multi-technique approach to follow the phase transformation pathway at multiple time points. In the present study, OCP has been synthesized from α-tricalcium phosphate (α-TCP), and subsequently scaled-up tenfold and hundredfold (100 mg → 10 g). The hydrolysis mechanism has been followed and described by using XRD and FTIR spectroscopy, as well as Raman and SEM. Gradual transformation into the OCP phase transpired through dicalcium phosphate dihydrate (brushite, DCPD, up to ~36%) as an intermediary phase. Furthermore, the obtained transitional phases and final OCP phases (across all scale-up levels) were tested with human bone marrow-derived mesenchymal stem cells (hBMSCs), in order to see how different phase mixtures affect the cell viability, and also to corroborate the safety of the scaled-up product. Twelve out of seventeen specimens showed satisfactory percentages of cell viability and confirmed the prospective use of scaled-up OCP in further in vitro studies. The present study, therefore, provides the first scale-up process of OCP synthesis, an in depth understanding of the formation pathway, and investigation of the parameters able to contribute in the OCP phase formation.

Identifiants

pubmed: 36979398
pii: biom13030462
doi: 10.3390/biom13030462
pmc: PMC10046208
pii:
doi:

Substances chimiques

octacalcium phosphate 13767-12-9
alpha-tricalcium phosphate 0
Calcium Phosphates 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Dalton Trans. 2009 Apr 21;(15):2665-72
pubmed: 19333487
Acta Biomater. 2018 Jul 1;74:478-488
pubmed: 29778896
J Mater Chem B. 2015 Jul 14;3(26):5318-5329
pubmed: 32262608
Biomaterials. 2002 Apr;23(8):1849-54
pubmed: 11950055
Biomed Res Int. 2013;2013:490946
pubmed: 23984373
Nat Commun. 2013;4:1507
pubmed: 23422675
J Dent Res. 1978 Jan;57(1):153-61
pubmed: 277490
Acta Biomater. 2010 Jun;6(6):1882-94
pubmed: 20040384
Sci Total Environ. 1991 Sep;107:179-203
pubmed: 1785049
Nanomedicine. 2011 Aug;7(4):428-34
pubmed: 21215328
Stem Cell Reports. 2015 Jun 9;4(6):1004-15
pubmed: 26070611
Environ Sci Technol. 2021 Nov 2;55(21):14407-14413
pubmed: 34724791
Calcif Tissue Int. 2008 Aug;83(2):146-54
pubmed: 18685796
Acta Biomater. 2021 Nov;135:27-47
pubmed: 34450339
Biomaterials. 2005 Jun;26(16):2787-94
pubmed: 15603774
Adv Dent Res. 1987 Dec;1(2):306-13
pubmed: 3504181
Methods Enzymol. 2013;532:129-44
pubmed: 24188765
Biomaterials. 2009 Feb;30(6):1005-14
pubmed: 19027945
Acta Biomater. 2023 Mar 1;158:1-11
pubmed: 36581004
Mater Sci Eng C Mater Biol Appl. 2010 Jan 30;30(2):245-254
pubmed: 30011614
Biomatter. 2012 Apr-Jun;2(2):53-70
pubmed: 23507803

Auteurs

Ilijana Kovrlija (I)

Rudolfs Cimdins Riga Biomaterials Innovation and Development Centre, Faculty of Materials Science and Applied Chemistry, Institute of General Chemical Engineering, Riga Technical University, Pulka 3, LV-1007 Riga, Latvia.

Ksenia Menshikh (K)

Center for Translational Research on Autoimmune and Allergic Disease-CAAD, Department of Health Sciences, Università del Piemonte Orientale, 28100 Novara, Italy.

Olivier Marsan (O)

CIRIMAT, Université de Toulouse, CNRS, Toulouse INP-ENSIACET, 4 Allée Emile Monso, CEDEX 4, 31030 Toulouse, France.

Christian Rey (C)

CIRIMAT, Université de Toulouse, CNRS, Toulouse INP-ENSIACET, 4 Allée Emile Monso, CEDEX 4, 31030 Toulouse, France.

Christèle Combes (C)

CIRIMAT, Université de Toulouse, CNRS, Toulouse INP-ENSIACET, 4 Allée Emile Monso, CEDEX 4, 31030 Toulouse, France.

Janis Locs (J)

Rudolfs Cimdins Riga Biomaterials Innovation and Development Centre, Faculty of Materials Science and Applied Chemistry, Institute of General Chemical Engineering, Riga Technical University, Pulka 3, LV-1007 Riga, Latvia.
Baltic Biomaterials Centre of Excellence, Headquarters at Riga Technical University, LV-1007 Riga, Latvia.

Dagnija Loca (D)

Rudolfs Cimdins Riga Biomaterials Innovation and Development Centre, Faculty of Materials Science and Applied Chemistry, Institute of General Chemical Engineering, Riga Technical University, Pulka 3, LV-1007 Riga, Latvia.
Baltic Biomaterials Centre of Excellence, Headquarters at Riga Technical University, LV-1007 Riga, Latvia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH